Home

Ultragenyx Pharmaceutical Inc. - Common Stock (RARE)

26.31
-1.10 (-4.01%)
NASDAQ · Last Trade: Jul 19th, 1:47 AM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors

Detailed Quote

Previous Close27.41
Open27.41
Bid26.15
Ask26.60
Day's Range26.00 - 27.50
52 Week Range26.00 - 60.37
Volume3,905,839
Market Cap1.86B
PE Ratio (TTM)-4.482
EPS (TTM)-5.9
Dividend & YieldN/A (N/A)
1 Month Average Volume2,559,393

Chart

About Ultragenyx Pharmaceutical Inc. - Common Stock (RARE)

Ultragenyx Pharmaceutical is a biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of rare genetic disorders. The company specializes in creating novel treatments targeting serious diseases caused by genetic mutations, particularly those that affect critical metabolic pathways. With a strong emphasis on research and development, Ultragenyx strives to bring hope and improved quality of life to patients living with rare conditions by harnessing cutting-edge science and technology to address unmet medical needs. Read More

News & Press Releases

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
NOVATO, Calif., July 18, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of 45,292 restricted stock units of the company’s common stock to 29 newly hired non-executive officers of the company. The awards were approved by the compensation committee of the company’s board of directors and granted under the Ultragenyx Employment Inducement Plan, with a grant date of July 16, 2025, as an inducement material to the new employees entering into employment with Ultragenyx in accordance with Nasdaq Listing Rule 5635(c)(4).
RARE Investors Have Opportunity to Join Ultragenyx Pharmaceutical Inc. Fraud Investigation with the Schall Law Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ultragenyx Pharmaceutical Inc. (“Ultragenyx” or “the Company”) (NASDAQ: RARE) for violations of the securities laws.
By The Schall Law Firm · Via Business Wire · July 18, 2025
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE
NEW YORK, July 18, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Ultragenyx Pharmaceutical Inc. (“Ultragenyx” or the “Company”) (NASDAQ: RARE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
By Pomerantz LLP · Via GlobeNewswire · July 18, 2025
FDA Delays Approval For Ultragenyx's Gene Therapy, But Not A Dealbreaker, Says Analystbenzinga.com
Ultragenyx's UX111 gene therapy faces FDA delay due to facility issues; analysts adjust price targets amid uncertain resubmission timeline.
Via Benzinga · July 14, 2025
Ultragenyx Pharma Takes Another Hit As FDA Slaps Its Gene Therapy With A Rejectioninvestors.com
The company has a bigger problem than just the FDA rejection, says one analyst. It's timeline to profitability is now longer.
Via Investor's Business Daily · July 14, 2025
Ultragenyx Pharmaceutical, Apple And Other Big Stocks Moving Lower In Monday's Pre-Market Sessionbenzinga.com
Via Benzinga · July 14, 2025
12 Health Care Stocks Moving In Friday's After-Market Sessionbenzinga.com
Via Benzinga · July 11, 2025
Ultragenyx Receives Complete Response Letter from FDA for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA)
Complete Response Letter (CRL) cited specific chemistry, manufacturing and controls (CMC) related observations that are resolvable
Market Monitor News July 11 BMO (Airline stocks UP - Ultragenyx Pharmaceuticals DOWN)chartmill.com
Investors shrug off tariff drama as earnings, chip euphoria, and airline optimism steal the show.
Via Chartmill · July 11, 2025
Breaking Down Ultragenyx Pharmaceutical: 4 Analysts Share Their Viewsbenzinga.com
Via Benzinga · July 10, 2025
Let's take a look at the stocks that are in motion in today's session.chartmill.com
Keep an eye on the top gainers and losers in Thursday's session, as they reflect the most notable price movements.
Via Chartmill · July 10, 2025
12 Health Care Stocks Moving In Thursday's Intraday Sessionbenzinga.com
Via Benzinga · July 10, 2025
Crude Oil Down Over 2%; Delta Air Lines Posts Upbeat Earningsbenzinga.com
Via Benzinga · July 10, 2025
Which stocks are experiencing notable movement on Thursday?chartmill.com
Stay up-to-date with the latest market trends in the middle of the day on Thursday. Explore the top gainers and losers during today's session in our detailed report.
Via Chartmill · July 10, 2025
US Stocks Mixed; Initial Jobless Claims Fallbenzinga.com
Via Benzinga · July 10, 2025
Ultragenyx, Mereo Hammered For Their Surprise Miss In Brittle Bone Diseaseinvestors.com
The study will continue onto a third and final analysis toward the end of the year.
Via Investor's Business Daily · July 10, 2025
Thursday's session: gap up and gap down stockschartmill.com
Let's have a look at what is happening on the US markets on Thursday. Below you can find the gap up and gap down stocks in today's session.
Via Chartmill · July 10, 2025
Ultragenyx, Mereo Shares Dive As Brittle Bone Disease Drug Misses Early Winbenzinga.com
Ultragenyx shares fall after Phase 3 study misses interim target, but analysts remain positive ahead of final OI data expected later this year.
Via Benzinga · July 10, 2025
Get insights into the top gainers and losers of Thursday's pre-market session.chartmill.com
Before the US market kicks off on Thursday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers.
Via Chartmill · July 10, 2025
12 Health Care Stocks Moving In Thursday's Pre-Market Sessionbenzinga.com
Via Benzinga · July 10, 2025
Methode Electronics, Ultragenyx Pharmaceutical And Other Big Stocks Moving Lower In Thursday's Pre-Market Sessionbenzinga.com
Via Benzinga · July 10, 2025
Why WK Kellogg Shares Are Trading Higher By Over 50%; Here Are 20 Stocks Moving Premarketbenzinga.com
Via Benzinga · July 10, 2025
Ultragenyx, Mereo Sink After Hours As Bone Drug Trial Continues Without Early Stop; Retail Traders Feel Selloff Is Overdonestocktwits.com
The companies now expect final data from the Orbit and Cosmic studies by the end of the year.
Via Stocktwits · July 10, 2025
12 Health Care Stocks Moving In Wednesday's After-Market Sessionbenzinga.com
Via Benzinga · July 9, 2025
What's going on in today's after hours sessionchartmill.com
Let's have a look at what is happening on the US markets after the closing bell on Wednesday. Below you can find the top gainers and losers in today's after hours session.
Via Chartmill · July 9, 2025